Montelukast API Market Segmentation by Type (Oral Solution, Chewable Tablet, and Tablet); and by Application (Urticaria, Asthma, Bronchospasm, Allergic Rhinitis, and Others)–Global Demand Analysis & Opportunity Outlook 2031
-
Product Code:
RP-ID-10094777 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-54
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
Global Montelukast API Market Highlights Over 2022 - 2031
The global montelukast API market is estimated to grow at a CAGR of ~4% over the forecast period, i.e., 2022-2031. Additionally, the market generated notable revenue in the year 2021. The growth of the market can be attributed to control the symptoms related to urticaria, asthma, bronchospasm, allergic rhinitis, and other diseases. The various symptoms that are controlled through montelukast API include wheezing, coughing, shortness of breath, and chest tightness. Asthma affected 7.7 percent of the total population in the U.S. in 2018 as per the Centers for Disease Control and Prevention. Therefore, the number of asthma cases has increased from the past year. Moreover, there has been an increase in the aged population that are more prone to urticaria, asthma, bronchospasm, allergic rhinitis, and other diseases as compared to the younger population.
GET A SAMPLE COPY OF THIS REPORT
The COVID-19 pandemic had a positive impact on the global montelukast API market. The price of medicines increased owing to an increase in patient demand and a decrease in supply considering the government’s restriction measures. Moreover, montelukast API was used during the pandemic to control the symptoms of the disease, such as breathing problems, sneezing, and others.
The global montelukast API market is segmented by application into urticaria, asthma, bronchospasm, allergic rhinitis, and others. Out of which, the asthma segment is expected to hold the largest share in the market by the end of 2031. This can be attributed to the surge in the cases of asthma across the globe. Furthermore, there has been an increase in the percentage of world’s population dealing with asthma problems as compared to the rest of the diseases. Therefore, it is expected to increase the growth of the global montelukast API market.
Global Montelukast API Market Regional Synopsis
Regionally, the global montelukast API market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region is anticipated to have the largest market share over the forecast period owing to the presence of major pharma players. Moreover, the market in the Asia Pacific region is estimated to witness modest growth over the forecast period on the back of an increase in the number of ageing population. As per the United Nations, 60% of the world’s total population lives in the Asia region, which accounted for 4.7 billion including the world's most populous countries, China and India.
Market Segmentation
Our in-depth analysis of the global montelukast API market includes the following segments:
By Type
-
Oral Solution
-
Chewable Tablet
-
Tablet
By Application
-
Urticaria
-
Asthma
-
Bronchospasm
-
Allergic Rhinitis
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Montelukast API Market
Growth Drivers
-
Increase in the demand for montelukast for the treatment of patients to control the disease symptoms
-
Rise in the number of asthma, allergic rhinitis, urticaria, and other illness cases
Challenges
-
Increase in the side effects of montelukast in patients
Key Companies Dominating the Global Montelukast API Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global montelukast API market that are included in our report are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Vintage Pharmaceuticals, LLC (Dun & Bradstreet, Inc.), SANYO CHEMICAL INDUSTRIES, LTD., Mylan (Viatris Inc.), Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Cipla Inc., and others.
Latest Developments in the Global Montelukast API Market:
-
28 November 2020: In Russia, Ukraine, Kazakhstan, and Uzbekistan, Dr. Reddy's Laboratories Ltd. purchased select Glenmark anti-allergy brands through an agreement with Glenmark Pharmaceuticals Ltd.
-
25 January 2022: Merck & Co., Inc., announced the completion of its acquisition of Themis, a company specializing in immune modulation therapies and infectious disease vaccines.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
FREQUENTLY ASKED QUESTIONS
Increase in the demand for montelukast for the treatment of patients to control the disease symptoms and rise in the number of asthma, allergic rhinitis, urticaria, and other illness cases are the major factors driving the growth of the montelukast API market.
The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2022-2031.
Increase in the side effects of montelukast in patients and lack of awareness related to relief from the use of montelukast are estimated to hamper the market growth.
Asia Pacific region will provide more business opportunities for growth of montelukast API market in future.
The major players in the market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, application, and by region.
Which segment captures the largest market size in application segment in the montelukast API market?
The asthma segment is anticipated to hold largest market size in value over the forecast period and display significant growth opportunities.
Please enter your personal details below
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Hikma Pharmaceuticals PLC
- Intas Pharmaceuticals Ltd.
- Vintage Pharmaceuticals LLC (Dun & Bradstreet, Inc.)
- SANYO CHEMICAL INDUSTRIES LTD
- Mylan (Viatris Inc.)
- Dr. Reddy’s Laboratories Ltd.
- Merck & Co. Inc.
- Cipla Inc.